Radius Health Inc (RDUS) : Rhenman Partners Asset Management Ab reduced its stake in Radius Health Inc by 4.76% during the most recent quarter end. The investment management company now holds a total of 100,000 shares of Radius Health Inc which is valued at $5,300,000 after selling 5,000 shares in Radius Health Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Radius Health Inc makes up approximately 0.85% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Alps Advisors Inc boosted its stake in RDUS in the latest quarter, The investment management firm added 12,086 additional shares and now holds a total of 60,460 shares of Radius Health Inc which is valued at $2,813,204. Radius Health Inc makes up approx 0.02% of Alps Advisors Inc’s portfolio. Bnp Paribas Arbitrage Sa added RDUS to its portfolio by purchasing 1,223 company shares during the most recent quarter which is valued at $50,449.
Radius Health Inc closed down -2.45 points or -4.62% at $50.55 with 21,76,677 shares getting traded on Thursday. Post opening the session at $53.29, the shares hit an intraday low of $50.22 and an intraday high of $53.29 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Radius Health Inc reported $-1.01 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.94.During the same quarter in the previous year, the company posted $-0.61 EPS.
Many Wall Street Analysts have commented on Radius Health Inc. Maxim Group Downgraded Radius Health Inc on Aug 4, 2016 to ” Sell”, Price Target of the shares are set at $24.H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.
Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.